Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

About Pieter Wolters

Pieter Wolters is currently the as President and CEO of OrthAlign Inc. Prior to OrthAlign, Pieter served as President & CEO of IsoTis, Inc., an orthopedics company based in Irvine, CA, from July 2004 until January 2008. During his tenure, sales increased from $25 million to well over $40 million, the company was listed on NASDAQ and acquired by Integra LifeSciences, Inc. Pieter joined IsoTis during its inception in The Netherlands in 1997 and was the companyÂâÂÂs CFO while the company went public and did two cross border M&A transactions. Pieter received his law degree from Leiden University, the Netherlands, in 1989.

Pieter Wolters Headquarter Location

Laguna Beach, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Pieter Wolters News

Interface Biologics Announces Series B Financing Round With DSM and BDC Capital

Jan 13, 2015

TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) - Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital. "Interface Biologics is a great strategic and a financial investment for DSM," remarked Pieter Wolters, Managing Director of DSM Venturing, the corporate venturing arm of Royal DSM, a EUR10 billion global science-based company active in health, nutrition and materials. "The fit with DSM's activities in Biomedical offers significant opportunities to create incremental value. " "BDC Capital has been an early and active investor in Interface Biologics since 2004," stated Dion Madsen, Senior Managing Partner in the Healthcare Venture Fund at BDC, "We believe the company is at the right stage to capitalize on the opportunity to work with a major strategic investor and accelerate the commercialization of its polymer technologies and the products that they enable. " "We're very pleased to have completed this Series B financing," commented Tom Reeves, President & CEO of Interface Biologics. "Having a strategic investor like DSM in combination with BDC underscores both IBI's success to date and the confidence that our investors have in our future. We look forward to working with DSM as we continue the commercial development of our surface modifying macromolecules and our drug delivery polymer technology platforms. " ABOUT INTERFACE BIOLOGICS, INC. Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are surface modifying macro-molecules and polymer enabled combination drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com . ABOUT DSM - Bright Science. Brighter Living.™ Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 24,500 employees deliver annual net sales of around EUR10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com . ABOUT DSM Venturing DSM Venturing is an active investor in DSM's strategic growth fields including Human Nutrition, Biomedical and Solar. DSM Venturing's mission is to explore and take positions in emerging companies in these strategic growth fields in order to create options for DSM and create value. For more information about DSM Venturing see www.dsm.com/venturing . ABOUT BDC Capital Healthcare Venture Fund BDC Capital's Healthcare Venture Fund invests in transformative Canadian companies that will dramatically increase healthcare productivity by reducing healthcare costs while improving patient health. The experienced team manages $270 million in capital across two different funds and invests in drugs, devices, diagnostics and digital health sectors. For more information, please visit www.bdccapital.ca/health . Contact Information

Pieter Wolters Investments

2 Investments

Pieter Wolters has made 2 investments. Their latest investment was in OrthAlign as part of their Series B on December 12, 2010.

CBI Logo

Pieter Wolters Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/8/2010

Series B

OrthAlign

$4M

No

1/21/2009

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/8/2010

1/21/2009

Round

Series B

Series A

Company

OrthAlign

Subscribe to see more

Amount

$4M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

0

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.